Chemical Biology & Drug Design · 2015 · 16 citations · 23 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsEnzyme InhibitionLead Compound DesignOncology PharmacologyStructure-activity Relationship AnalysisTyrosine Kinase InhibitorsAnticancer ActivityAromatic Ring ReplacementChemical Structure-activity RelationshipsChemical Synthesis Of AnaloguesMedicinal Chemistry ApplicationsMild Reaction ConditionsPyrimidine AnalogsPyrimidine Analogues
A series of tetrahydrobenzothieno[2,3-d]pyrimidine derivatives were designed, synthesized, and evaluated as inhibitors of FGFR1. These analogs were synthesized via Gewald's reaction under mild conditions. The structures of the synthesized compounds were characterized by spectroscopic data (IR, (1) H NMR and MS). Their antitumor activities were evaluated against H460, A549 and U251 cell lines in vitro. Results revealed that the tested compounds showed moderate antitumor activities. Structure-activity relationship analyses indicated that compounds with an aromatic ring substituted in the C-2 position or with larger molecules such as 3g, 4c, and 7 were more effective than others. The compound, 3g (78.8% FGFR1 inhibition at 10 μm), was identified to have the most potent antitumor activities, with IC50 values of 7.7, 18.9, and 13.3 μm against the H460, A549, and U251 cell lines, respectively. Together, the results suggested that tetrahydrobenzothieno[2,3-d]pyrimidine derivatives may serve as a potential agent for the treatment of FGFR1-mediated cancers.
23
Vito Guagnano, Pascal Furet, Carsten Spanka et al. · Journal of Medicinal Chemistry · 2011 · 489 citations · Full text
A Structure-Guided Approach to Creating Covalent FGFR Inhibitors
Wenjun Zhou, Wooyoung Hur, Ultan McDermott et al. · Chemistry & Biology · 2010 · 138 citations · Full text